Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — DNB Carnegie's Nordic Healthcare Conference 2026
32 slides from Nykode Therapeutics Asa's conference presentation, Mar 10, 2026
Slide 1: DNB Carnegie's Nordic Healthcare Conference
DNB Carnegie’s Nordic Healthcare Conference Stockholm | March 10, 2026
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Clinical stage leader in antigen-specific precision immunotherapy
Clinical stage leader in antigen-specific precision immunotherapy NYKODE THERAPEUTICS (NYKD-OL) Clinical stage immunotherapy company Targeting antigens to Antigen-Presenting Cells (APCs) to direct tailor-made immune responses with focus on oncology and autoimmune diseases Focused strategy to r
Slide 4: Focused strategy with clear value drivers
Focused strategy with clear value drivers Abi-suva (VB10.16) Randomized clinical trial (Abili-T) in 1L R/M head and neck cancer on track to deliver meaningful interim results within 2027 VB10.NEO Clinically proven Individualized Neoantigen Therapy (INT) APCs Tolerance Antigen Specific Immune Toleran
Slide 5: Targeting APCs drives precise immune response tailored to disease setting
Targeting APCs drives precise immune response tailored to disease setting APCs play key role in immune regulation Nykode Modular Design to target APCs • Targets antigen-presenting cells (APCs), the key regulators of immune responses Targeting unit → binds APCs • Nykode technology delivers disease-sp
Slide 6: Focused execution on oncology and autoimmune diseases
Focused execution on oncology and autoimmune diseases – significant untapped potential remains What Nykode’s proprietary APC targeting technology Current focus • Abi-Suva • ASIT • VB10.NEO platform Oncology Auto-immune Opportunity Infectious Allergy Trans-plants Nykode Therapeutics | DNB Carnegie In
Slide 7: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash runway Next 12 months Next 12-24 months Cash runway into 2028-2029* C-03 interim data (ICHNO Q1 26 Abili-T first interim analysis (2027) + additional conference Q2 26) Cash runway exceeding Continued expected key peer significant in
Slide 8: Abi-suva in HPV16+ cancers
Abi-suva in HPV16+ cancers Nykode Therapeutics | DNB Carnegie Investor Presentation | Non-confidential 8
Slide 9: Initial focus in head & neck cancer with expansion across HPV16+ tumors
Initial focus in head & neck cancer with expansion across HPV16+ tumors Current focus of Abi-suva Future potential for Abi-suva 1L r/m HNSCC HPV16+ driven cancers Incidence of HPV16+ driven HNSCC cancers Incidence of HPV16+ driven cancers in EU in EU and US is ~ 63.0001,2,3 and US is ~ 134.0001,2,3
Slide 10: HNSCC: HPV+ and HPV- head and neck cancer are two distinct cancer types
HNSCC: HPV+ and HPV- head and neck cancer are two distinct cancer types HNSCC patients Patients are divided into two distinct disease entities with very different prognoses and management HPV16- HNSCC HPV16+ HNSCC Exhibits EGFR overexpression in up to 90% of tumors, Tumor growth driven by HPV viral
Slide 11: Abi-suva shows strong and consistent clinical effect across several trials
Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications Promising increase in overall response rate Overall response rate (ORR) indicates a strong (ORR) compared to CPI monotherapy clinical effect with abi-suva + atezolizumab (VB- C-02) Objective respo
Slide 12: Strong overall survival in 2L+ cervical cancer
Strong overall survival in 2L+ cervical cancer Overall survival of 24.7 mos in PD-L1+ patients Overall survival is longer than CPI monotherapy treated with abi-suva + atezolizumab for 12 historic controls months mOS compared to SOC 24,7 ~109% 13,9 10,6 11,0 24,7 13,9 10,6 11,0 Abi-suva + Atezo Pembr
Slide 13: VB-C-01 Strong monotherapy activity observed in HSIL patients
VB-C-01 Strong monotherapy activity observed in HSIL patients Patients showed consistent reduction in lesion size and regression of lesion severeness • Strong monotherapy efficacy observed in premalignant cervical lesions (CIN2/3, HSIL patients) • Safe and well tolerated Nykode Therapeutics | DNB Ca
Slide 14: Immune responses are significantly correlated with clinical effect across trials
Immune responses are significantly correlated with clinical effect across trials C-02 2L+cervical cancer in C-01 HSIL patients monotherapy combination with atezolizumab 1500 1000 • Significant correlation between p=0.0113 500 250 HPV16-specific T cell responses and clinically SFU/106 PBMC 200 releva
Slide 15: Abili-T randomized controlled trial designed to demonstrate contribution of abi-suva
Abili-T randomized controlled trial enrolling up to 100 patients, designed to demonstrate contribution of abi-suva Key inclusion Treatment Endpoints criterion ORR • HPV16+ r/m HNSCC Abipapogene suvaplasmid + pembrolizumab PFS DOR • PD-L1+ R RMDOR • Measurable disease DCR (1:1) • ECOG PS 0-1 OS • GRI
Slide 16: Significant advancements in the Abili-T trial
Significant advancements in the Abili-T trial Achieved since announcement of trial (August 2025): Protocol submitted to UK regulatory authorities in November Protocol submitted to relevant EU regulatory authorities in December Secured supply of pembrolizumab with MSD Protocol approved by UK
Slide 17: VB10.NEO Individualized NeoAntigen Therapy
VB10.NEO Individualized NeoAntigen Therapy Nykode Therapeutics | DNB Carnegie Investor Presentation | Non-confidential 17
Slide 18: Individualized neoantigen therapies (INT) entering defining period
Individualized neoantigen therapies (INT) entering defining period Nykode well-positioned as most attractive unencumbered INT Potential to treat all tumor types Highest investments in INT to date with more than 10 ongoing Ph2 and Ph3 clinical trials Expected key peer readouts within 12 months Nykode
Slide 19: Individualized Neoantigen Therapy
Individualized Neoantigen Therapy 5. Treatment with 1. Biological Material INT Tumor biopsy & blood Personalized vaccines targeting tumor-specific mutations sample Neoantigens • Tumor-specific mutations not found in healthy tissue Individualized INT Platform • Fully personalized per patient Neoantig
Slide 20: VB10.NEO: Nykode's individualized cancer vaccine
VB10.NEO: Nykode’s individualized cancer vaccine Promising immunogenicity data 2 clinical trials in recurrent/ metastatic patients across >10 solid tumors types 100% of patients in N-02 showed vaccine- induced immune responses VB10.NEO Proprietary neoantigen selection method Fully individualized
Slide 21: VB10.NEO delivers on all key success factors for an ideal INT candidate
VB10.NEO delivers on all key success factors for an ideal INT candidate Clinical Antigen selection Supply chain Costs experience NeoSELECT – Nykode has a Nykode’s DNA based Nykode’s two Nykode’s robust and proven therapy has both clinical trials show proprietary supply chain with advance on cost and
Slide 22: Strong immune responses across basket trials with heavily pre-treated patients
Strong immune responses across 2 basket trials with heavily pre-treated patients N-01 and N-02 both show vaccine induce immune response N-01 100 Strong vaccine-induced immune responses, N-02 85 85 88 even in heavily pre-treated late-stage patients after few vaccinations* 58 45 Persistent expansion o
Slide 23: VB10.NEO - clinically-proven supply chain with a competitive manufacturing process
VB10.NEO - clinically-proven supply chain with a competitive manufacturing process Nykode has successfully manufactured >60 Competitive turn-around-time from patient biopsy to INT vaccines patient treatment Turn-Around-Time (weeks) 5. Treatment with 1. Biological Material INT Tumor biopsy & blood sa
Slide 24: pDNA offers significantly less complex production process and COGS
pDNA offers significantly less complex production process and COGS for individualized NeoAntigen therapy High potential for fast turn-around-time and lower COGS compared to mRNA pDNA Fermentation DNA Fill Product QA and Purification release mRNA Fermentation DNA In vitro Downstream mRNA QA LNP Fill
Slide 25: Antigen-Specific Immune Tolerance
Antigen-Specific Immune Tolerance Nykode Therapeutics | DNB Carnegie Investor Presentation | Non-confidential 25
Slide 26: A new way of thinking about autoimmune disease treatment
A new way of thinking about autoimmune disease treatment The Problem The Future Current treatment focus on symptom management -- do not address the underlying root cause of disease . Antigen-Specific Immune Tolerance Unsolved Side effects frequently impairing the quality of life of is a new way of a
Slide 27: Nykode's preclinical data shows promise across several therapeutic areas
Nykode’s preclinical data shows promise across several therapeutic areas Neurology Endocrinology Dermatology Therapies to halt or slow immune- Therapy to provide disease Therapies to ameliorate Therapeutic Area mediated nerve damage and modifying treatment for Type 1 autoimmune skin diseases and pro
Slide 28: Nykode's ASIT platform shows Best-In-Class potential
Nykode’s ASIT platform shows Best-In-Class potential Long durable reversion of disease symptoms Efficacy is dependent on the proprietary APC targeting Ag selection AI competencies for antigen Integrity selection and optimal product design Expression Secretion Nykode Therapeutics | DNB Carnegie Inves
Slide 29: Nykode's ASIT platform impacts all major arms of the immune system
Nykode’s ASIT platform impacts all major arms of the immune system Increase Reduce auto- Reduce regulatory antibodies effector T cells T cells anti-MOG (35-55) IgG Foxp3+ Treg cells Day 7 % Foxp3+ of CD4+Thy1.2+ cells ✱✱✱ PBS 100 MOG-specific IgG (µg/mL) 100 ✱ Targeted vaccine 1 75 80 50 ✱ 60 40 25
Slide 30: Outlook
Outlook Nykode Therapeutics | DNB Carnegie Investor Presentation | Non-confidential 30
Slide 31: Well-positioned to execute strategy and meet inflection points
Well-positioned to execute strategy and meet inflection points Cash runway Next 12 months Next 12-24 months Cash runway into 2028-2029* C-03 interim data (ICHNO Q1 26 Abili-T first interim analysis (2027) + additional conference Q2 26) Cash runway exceeding Continued expected key peer significant in
Slide 32: Q&A Contact: IR@nykode.com
Q&A Contact: IR@nykode.com Nykode Therapeutics | DNB Carnegie Investor Presentation | Non-confidential
Nykode Therapeutics — DNB Carnegie's Nordic Healthcare Conference 2026 on 6ix